目的 開(kāi)展紫杉醇所致眼部損傷藥學(xué)干預(yù),探討其發(fā)生機(jī)制,并提出防治建議。方法 分析紫杉醇眼部損傷與劑型的關(guān)系,以紫杉醇化療致眼部損傷個(gè)案為藥學(xué)干預(yù)對(duì)象,監(jiān)護(hù)患者眼部損傷不良反應(yīng),記錄不同劑型紫杉醇致眼部損傷情況,探討減輕ADR的防治實(shí)施。結(jié)果 紫杉醇導(dǎo)致眼部損傷存在劑量相關(guān)性,紫杉醇脂質(zhì)體替代紫杉醇注射液不能減輕眼部損傷,白蛋白結(jié)合型紫杉醇有明確的眼損傷,避免特殊人群使用。結(jié)論 充分認(rèn)識(shí)紫杉醇致眼部損傷機(jī)制及防治措施,開(kāi)展有效的藥學(xué)干預(yù),可使患者最大獲益。

Objective To carry out the pharmaceutical intervention of eye damage caused by paclitaxel, and to explore the pathogenetic mechanism, and to offer precautionary and control suggestions. Methods To analyze the relationship between eye damage and dosage form of paclitaxel. A case of eye damage induced by chemotherapy with paclitaxel was used as pharmaceutical intervention. The adverse drug reaction (ADR) of eye damage was monitored, and eye damage induced by paclitaxel with different dosage forms was recorded, and to explore the precautionary and control implementation of reducing ADR. Results Eye damage caused by paclitaxel was dose-relatived. Paclitaxel Liposome instead of Paclitaxel Injection could not induce the eye damage. Abraxane had specific eye damage, and it should be avoided using for special crowd. Conclusion Fully understanding the mechanism and prevention measures of eye damage caused by paclitaxel and carrying out the effective pharmaceutical intervention can make the biggest benefit for patients.